Multiple Myeloma: A Practical Guide to Current Management

More documents

Recommendations

Info

Jointly Sponsored by The American School of Oncology and The University of Alabama, School of Medicine Division of Continuing Medical Education. Published by: Network for Medical Communication and Research, LLC. 780 Johnson Ferry Road Suite 100 Atlanta, GA 30342 Editorial and Publishing Services by: CJP Medical Communications Carden Jennings Publishing Co., Ltd. 375 Greenbrier Drive, Suite 100 Charlottesville, VA 22901 “Multiple Myeloma: A Practical Guide to Current Management” has been made possible by an unrestricted educational grant from Celgene. Multiple Myeloma: A Practical Guide to Current Management is produced by The American School of Oncology. The American School of Oncology is a division of Leading Educational Resource Network, LLC (LERN). LERN is a division of the Network for Medical Communication and Research, LLC (NMCR). NMCR is solely responsible for this program’s content. Although NMCR makes every effort to ensure that the information in our programs is accurate and timely, we would like to clarify that when clinical matters are discussed and/or presented, the opinions are those of the discussants only, and not necessarily those of NMCR. Moreover, although we have made our best efforts to identify and integrate the most qualified medical professionals and key opinion leaders in our programs, NMCR makes no warranty or guarantee concerning the accuracy or reliability of the content presented. NMCR also assumes no liability for errors that may be in any source material. Neither NMCR nor any of its subsidiaries are affiliated or formally endorsed by any medical society. Copyright 2005 NMCR, LLC. All rights reserved.
Introductory Letter Multiple Myeloma: A Practical Guide to Current Management Dear Colleague, Options for management of newly diagnosed and relapsed multiple myeloma have increased significantly in the recent past, and additional novel therapies will soon be added to our armamentarium. Thalidomide and lenalidomide, the proteasome inhibitor bortezomib, autologous and mini-allotransplantation, and the conventional agents dexamethasone and melphalan all have roles to play in current therapeutic strategies. Appropriate sequencing of these therapies and skillful management of associated toxicities is mandatory if outcomes are to be optimized for patients with myeloma. To provide a broad international perspective regarding the management of multiple myeloma, a panel of experts was convened prior to the 10th International Myeloma Workshop held in Sydney, Australia, in April 2005. As chairperson of a roundtable discussion, I charged the group with the task of providing practical, evidence-based guidelines for management that would be useful for the practicing oncologist and hematologist. In many cases a clear consensus of the participating experts could be achieved, while in others there were defensible differences of opinion. I hope you will find this monograph to be of value in the management of your patients with multiple myeloma. Sincerely, A Roundtable Discussion of the Role of Thalidomide by International Key Opinion Leaders Keith Stewart, MB. CHB. Mayo Clinic Scottsdale, Arizona This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. The information contained herein is based upon sources believed to be accurate and reliable. We have exercised reasonable care to assure the accuracy of the information. However, no representation or warranty is made as to such accuracy. Readers should check primary sources where appropriate and use the traditional research techniques to make sure that the information has not been affected or changed by recent developments.
Page 1: Multiple Myeloma: A Practical Guide
Page 5 and 6: Monograph Overview Target Audience:
Page 7 and 8: Faculty Disclosures Dr. Ivan Borrel
Page 9 and 10: Multiple Myeloma: A Practical Guide
Page 32: 780 Johnson Ferry Rd. Suite 100 Atl

Multiple Myeloma: A Practical Guide to Current Management

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?